← Compound index
COMPOUND RECORD / CRYSTAGEN

CrystagenКристаген

A short-peptide product described in institute reports as containing glutamate, aspartate and proline. The reports do not establish that the tested product was chemically identical to isolated Glu–Asp–Pro (EDP).

Source linked

What the studies found

Comparison in people · 2006

Crystagen after radiation exposure: Medical Center clinical report

In the low-dose radiation subgroup, CD4-positive cells were 32.1% after Crystagen plus usual care versus 29.7% after usual care alone. The table marks the change from baseline, with no reported between-group test.

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model 70 adults aged 38–69: 40 received adjunctive Crystagen and 30 received conventional therapy alone. Each arm included patients with low-dose radiation exposure and patients after radiation and chemotherapy.

Design 40 received Crystagen plus conventional therapy and 30 received conventional therapy alone. The reported oral regimen was one to three capsules two to three times daily for 15–20 days. Table 2 covers the low-dose radiation subgroup (20 treated, 15 comparator).

CD4-positive cells in the low-dose radiation subgroup
32.1 ± 1.8% with Crystagen vs 29.7 ± 2.4% with conventional care. Shared baseline 26.3 ± 2.4%.The Crystagen value is marked p < 0.05 versus baseline.
CD3-positive cells in the low-dose radiation subgroup
53.3 ± 2.2% with Crystagen vs 49.3 ± 2.3% with conventional care. Shared baseline 45.1 ± 2.1%.The Crystagen value is marked p < 0.05 versus baseline.
IgG in the low-dose radiation subgroup
15.2 ± 1.5 g/L with Crystagen vs 15.4 ± 1.4 g/L with conventional care. Shared baseline 15.1 ± 1.2 g/L.The table gives no significance mark for IgG.

Important limitations

  • The report gives one shared baseline column and leaves allocation and masking unspecified. The low-dose radiation table covers 20 treated patients and 15 conventional-care patients. The clinical product is insufficiently characterized to establish equivalence with synthetic EDP.
  • The report uses a shared baseline and gives no direct between-group statistical test for these outcomes.

Reports on clinical studies of CYTOMAX and CYTOGEN products; PDF page 109 · Institute report / commercial reproduction

Original source or citation ↗

Study results and tables ↗

Observational study · 2013

Oral peptide combinations in Agent Orange-exposed veterans with immune deficiency

Study of multiple preparations

IgG
1,202.27 → 1,445.20 mg/dLBefore and after the combination.p<0.01
CD4 cells
501.96 → 569.33 cells/µLp<0.01
IgM
126.56 → 132.46 mg/dLp<0.01

In 150 veterans, mean IgG rose from 1,202.27 to 1,445.20 mg/dL and CD4 cells from 501.96 to 569.33 cells/µL (both p<0.01). CD19 and the CD4/CD8 ratio did not change significantly.

More reported outcomes
CD3 and CD8 cells
963.01 → 1,088.78 and 389.72 → 438.10 cells/µLp<0.01 and p<0.05, respectively
IgA, CD19 and CD4/CD8 ratio
No statistically significant changep>0.05
Author-defined overall outcome
105/150 good, 45/150 fairNo untreated group for this rating.
Study notes · methods, sources and limitations

Participants or model 150 veterans with immune deficiency in the Joint Vietnam–Russia Program 33. The same 150 are shown before and after treatment.

Design The researchers compared immunoglobulins and lymphocyte markers before and after the 20-day regimen. Tables show paired assessment denominators of 150. The reference laboratory column is a population benchmark.

Important limitations

  • This was a before-and-after study of three products with no concurrent untreated group. Individual product effects and effects on infection risk remain uncertain. Program 33 reports 300 participants across two clinical series. The relationship between the two participant lists remains unverified.

Journal of Tropical Science and Technology. 2013;(2):78–84. · Publication record

Original source or citation ↗

Study results and tables ↗

Observational study · 2012

Oral peptide combinations for prostate symptoms in Agent Orange-exposed veterans

Study of multiple preparations

International Prostate Symptom Score
20.94 ± 8.49 → 8.46 ± 2.78p<0.01
Urinary flow
4.9 ± 2.3 → 9.1 ± 2.5 mL/sp<0.001
Urinary symptom quality-of-life item
4.10 ± 1.01 → 2.53 ± 0.61p<0.001

In 150 veterans, mean prostate symptom score (IPSS) fell from 20.94 to 8.46 (p<0.01) and urinary flow increased from 4.9 to 9.1 mL/s (p<0.001). This before-and-after comparison tested four oral products together.

More reported outcomes
Severe urinary symptoms
61/150 → 14/150IPSS ≥20. The paper reports 40.7% → 9.3%.
Study notes · methods, sources and limitations

Participants or model 150 veterans with benign prostatic hyperplasia. The same 150 are shown before and after treatment.

Design Prospective, within-person comparison of urinary symptoms, quality of life and urine flow before and after adjunctive treatment. All reported denominators below are 150 at each assessment.

Important limitations

  • There was no concurrent untreated comparator or single-product arm. The results cover the combination. The tested Veziliut lot and its peptide content remain unclear. The two 150-person publications are part of the same parent program, and participant overlap remains unverified.

Journal of Tropical Science and Technology. 2012;(1):85–93. · Publication record

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Crystagen

Research background

Crystagen is an oral peptide preparation studied for immune markers after radiation exposure. Experimental work with the Glu–Asp–Pro (EDP) tripeptide has its own formulation and methods.

More study findings

Lab research · 2016

Vladonix, Endoluten and other peptides in cultured human blood cells

Findings for this preparation

Crystagen and Cortexin · lysate IL-18
75.10 and 60.02 vs 39.06 pg/mLEach preparation versus saline. Crystagen’s printed interval is inconsistent.p = 0.004 and p = 0.04, respectively.

In cultured blood cells, Crystagen raised lysate IL-18 to a printed median of 75.10 vs 39.06 pg/mL. The printed Crystagen interquartile range excludes its median.

Study notes · methods, sources and limitations

Participants or model Peripheral-blood mononuclear cells from 15 volunteers. Mean donor age 41 ± 19 years, 73% men.

Design Saline-controlled cultures from 15 donors, 0.4 µg/mL for 24 hours. Lysate and supernatant were analyzed separately.

Important limitations

  • The volunteers donated blood and did not receive treatment. Culture concentrations cannot establish oral exposure or clinical effects. The Crystagen IL-18 median lies outside its printed interquartile interval. Some narrative percentages differ from ratios calculated from tabulated medians.
  • The experiment measures cytokine concentrations after direct contact with cells. The clinical meaning and relevance to swallowing a capsule remain unknown.

Actual Problems of Humanities and Natural Sciences. 2016;12-3:97–100 · Original journal article

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2018

Pinealon and Crystagen in a 28-rower study

Study of multiple preparations

Hemoglobin
136.1 → 134.4 g/L active; 137.0 → 141.6 g/L controlSelected Table 6.6 means.
Leukocytes
5.2 → 5.1 vs 5.9 → 5.8 ×10⁹/LActive versus ordinary-training group, Table 6.6.
Oxidative markers
Authors described lower lipid-peroxidation productsBiomarker results are separate from timed rowing.

The monograph reports changes in oxidative biomarkers, alongside little change in several blood counts. It does not establish individual effects of Pinealon and Crystagen.

Study notes · methods, sources and limitations

Participants or model 28 rowers aged 18–30, 18 men and 10 women. Active and ordinary-training groups n=14 each.

Design The authors describe stratified randomization and clinical, laboratory and oxidative-status measurements. Active supplement selection was individualized.

Reported study exposure
One oral capsule twice a day during meals for ten days in the active group. Individual capsule payload and allocation by preparation are not recoverable for each endpoint.

Important limitations

  • The comparison group continued usual training. Heterogeneous formulations and small groups limit attribution. Participant overlap with Emirova’s older cytamin series remains uncertain.

Molecular and Cellular Mechanisms of Peptidergic Regulation of Brain Functions, Chapter 6.1.2, pp. 168–182 · Molecular and Cellular Mechanisms of Peptidergic Regulation of Brain Functions, Chapter 6.1.2, pp. 168–182

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2012

Pinealon plus Crystagen in rhythmic gymnastics

Study of multiple preparations

Morning recovery heart rate
83.8±1.5 → 74.2±2.5 beats/minCombination arm, p<0.05 within group. Comparison arm 86.6±3.2 → 88.4±3.6.
Evening recovery heart rate
87.4±2.3 → 77.6±1.7 beats/minCombination arm, p<0.05 within group. Comparison arm 84.3±3.1 → 83.7±2.4.
During routines and individual elements
No statistically significant changes reportedTraining heart-rate measures are separate from performance judged in competition.

Morning recovery heart rate decreased from 83.8 to 74.2 beats/min in the combined arm. Heart rate during full routines and individual elements showed no significant change.

Study notes · methods, sources and limitations

Participants or model 20 elite female rhythmic gymnasts. Combination n=12; usual training n=8.

Design Author-described stratified assignment. Heart rate during training tasks and recovery, with other laboratory and self-reported outcomes.

Reported study exposure
One capsule of each oral product twice daily with meals for 20 days. The comparison was usual training without matched placebo.

Important limitations

  • Both preparations were given together. Publications from the same group may repeat this cohort.
  • The report cannot isolate Pinealon or Crystagen and does not demonstrate competitive benefit.

St. Petersburg Institute of Bioregulation and Gerontology, reproduced methodological report, Tables 2–3 · St. Petersburg Institute of Bioregulation and Gerontology, reproduced methodological report, Tables 2–3

Original source or citation ↗

Study results and tables ↗

Observational study · 2016

Personified prevention of diseases under the conditions of the Far North

Study of multiple preparations

Sick-leave certificates
18 → 102014 → 2015; whole program
Days unfit for work
119 → 602014 → 2015; whole program
Seasonal morbidity
No statistically reliable improvement reported

A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.

More reported outcomes
Narrative/table discrepancy
Narrative 43.4% decrease; Table 2 gives 119 → 60 daysUnresolved source discrepancy; not interchangeable figures
Study notes · methods, sources and limitations

Participants or model 113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.

Design 113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.

Important limitations

  • One shared cohort, not a separate trial for each named preparation. Genotype-guided assignments and other care prevent isolating a product effect. The narrative reports a 43.4% reduction, which does not reconcile with the table’s 119 → 60 days. The background 11,000-worker claim is not this cohort.

Vrach. 2016;(6):64–66 · Journal publication

Original source or citation ↗

Study results and tables ↗

Research record · 2014

Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process

Study of multiple preparations

Crystagen response
B-cell activation reported; no aging-spleen cell renewal
Other peptide responses
Vilon: reduced T-helper apoptosis; Thymogen: B-cell proliferation with less apoptosis

Crystagen activated B-cell measures but did not cause renewal of the aging spleen. Vilon was associated with lower T-helper-cell apoptosis; Thymogen with lower apoptosis and increased B-cell proliferation.

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model Experimental aging-spleen work; species and assay design not specified in the indexed abstract.

Design Experimental aging-spleen work; species and assay design not specified in the indexed abstract.

Important limitations

  • The abstract does not establish the experimental model sufficiently to classify this as a human study or a specific animal/cell design. Commercial product equivalence is unverified.

Advances in gerontology = Uspekhi gerontologii 2014 · Journal publication

Original source or citation ↗

Study results and tables ↗

Research updates ↗

Compound class
Peptide product / formulation research
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
St. Petersburg Institute of Bioregulation and Gerontology · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Institute report; independent peer review not established

Study methods

Randomization, blinding and product characterization unresolved

Independent replication

Independent replication not established in this collection

Source access

See source-specific abstracts, institute reports and explicit review scopes

Safety evidence

Systematic safety assessment incomplete

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

View this preparation in the Khavinson evidence map ↗

PATENT RESEARCH / COLLECTION UPDATED 7 NOVEMBER 2026

Patents and claimed inventions

These 1 grouped records distinguish claimed molecules, uses, formulations and related chemistry. Patent disclosure does not establish clinical benefit or approval.

2011 · US8057810B2 · Crystagen research trail: defined EDP peptideMolecule · 55.7 ± 2.6% after peptide-containing care versus 49.3 ± 2.2% conventional care; baseline 43.5 ± 2.3%

Reported findings

Selected T-cell markers changed during EDP-containing care, without established clinical immune-rejuvenation outcomes.

CD3-positive cells
55.7 ± 2.6% after peptide-containing care versus 49.3 ± 2.2% conventional care; baseline 43.5 ± 2.3%Immune-marker endpoint; significance annotation has an ambiguous comparator footnote
CD4/CD8 ratio
1.4 after peptide versus 1.2 conventional care; baseline 1.1Surrogate marker, not a disease or survival endpoint
All reported results, comparisons and limitations →

Molecule. This family concerns the Glu-Asp-Pro sequence and proposed immune or geroprotective applications.

The sequence-level connection does not authenticate the composition or efficacy of a commercial Crystagen product.

Publication
US8057810B2 ↗ · 2011-11-15
Earliest priority / filing
2006-05-30 / 2007-03-02
Original applicant / assignee
SIA Peptides OOO
Indexed status
Active · checked 2026-11-06
Patent family
38314259 · family publications are related filings, not independent studies.
Original title, inventors and related publications

Peptide substance revealing an immunogeroprotective effect, pharmaceutical composition on its base and the method of its application

Inventors: Vladimir Khatskelevich Khavinson; Evgeny Iosifovich Grigoriev; Vladimir Victorivich Malinin; Galina Anatolievna Ryzhak.

US8057810B2 · EP2032595B1 · KR101382947B1 · ATE513845T1 · DK2032595T3 · EA010575B1 · IL194499A0 · RU2301074C1 · UA91135C2 · WO2007139435A1

Original patent PDF ↗

Read source review →

Status is an indexed snapshot, not an official legal assessment. Search the patent collection and read the method →

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Observational study · 2013

Oral peptide combinations in Agent Orange-exposed veterans with immune deficiency

In 150 veterans, mean IgG rose from 1,202.27 to 1,445.20 mg/dL and CD4 cells from 501.96 to 569.33 cells/µL (both p<0.01). CD19 and the CD4/CD8 ratio did not change significantly.

Study notes and original source
2013Uncontrolled human reportFull text available

Oral peptide combinations in Agent Orange-exposed veterans with immune deficiency

Vladoniks, Vezugen and Kristagen as named in the paper. Branded oral preparations.

Hoàng Văn Huấn, Phạm Khắc Linh, Nguyễn Như Nghĩa, and colleagues · Journal of Tropical Science and Technology. 2013;(2):78–84.

In 150 veterans, mean IgG rose from 1,202.27 to 1,445.20 mg/dL and CD4 cells from 501.96 to 569.33 cells/µL (both p<0.01). CD19 and the CD4/CD8 ratio did not change significantly.

Results and tables

Reported findings and study design

The researchers compared immunoglobulins and lymphocyte markers before and after the 20-day regimen. Tables show paired assessment denominators of 150. The reference laboratory column is a population benchmark.

Population or model 150 veterans with immune deficiency in the Joint Vietnam–Russia Program 33. The same 150 are shown before and after treatment.

Dose, route and schedule

Vladoniks, Vezugen and Kristagen were taken orally for 20 days. The paper lists 0.2 g of each preparation. It does not give purified peptide content or capsule frequency.

Protocol source ↗ · Original journal PDF, methods and Tables 1–6. Parent program report and Ministry of Defence project citation checked.

Results · Original journal PDF, methods and Tables 1–6. Parent program report and Ministry of Defence project citation checked.
MeasureResultComparison, timing and statistics
IgG1,202.27 → 1,445.20 mg/dLBefore and after the combination. · p<0.01
CD4 cells501.96 → 569.33 cells/µLp<0.01
IgM126.56 → 132.46 mg/dLp<0.01
CD3 and CD8 cells963.01 → 1,088.78 and 389.72 → 438.10 cells/µLp<0.01 and p<0.05, respectively
IgA, CD19 and CD4/CD8 ratioNo statistically significant changep>0.05
Author-defined overall outcome105/150 good, 45/150 fairNo untreated group for this rating.

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
150 veterans with immune deficiency in the Joint Vietnam–Russia Program 33. The same 150 are shown before and after treatment.
Source reviewed
Original journal PDF, methods and Tables 1–6. Parent program report and Ministry of Defence project citation checked.
Study limitations
  • This was a before-and-after study of three products with no concurrent untreated group. Individual product effects and effects on infection risk remain uncertain.
  • Program 33 reports 300 participants across two clinical series. The relationship between the two participant lists remains unverified.

Reviewed 2026-11-14.

Read the source ↗

Observational study · 2012

Oral peptide combinations for prostate symptoms in Agent Orange-exposed veterans

In 150 veterans, mean prostate symptom score (IPSS) fell from 20.94 to 8.46 (p<0.01) and urinary flow increased from 4.9 to 9.1 mL/s (p<0.001). This before-and-after comparison tested four oral products together.

Study notes and original source
2012Uncontrolled human reportFull text available

Oral peptide combinations for prostate symptoms in Agent Orange-exposed veterans

Veziliut, Vezugen, Kristagen and Ventfort as named in the paper. Branded oral preparations.

Hoàng Văn Huấn, Phạm Khắc Linh, Nguyễn Như Nghĩa, and colleagues · Journal of Tropical Science and Technology. 2012;(1):85–93.

In 150 veterans, mean prostate symptom score (IPSS) fell from 20.94 to 8.46 (p<0.01) and urinary flow increased from 4.9 to 9.1 mL/s (p<0.001). This before-and-after comparison tested four oral products together.

Results and tables

Reported findings and study design

Prospective, within-person comparison of urinary symptoms, quality of life and urine flow before and after adjunctive treatment. All reported denominators below are 150 at each assessment.

Population or model 150 veterans with benign prostatic hyperplasia. The same 150 are shown before and after treatment.

Dose, route and schedule

The 20-day oral regimen lists Veziliut, Vezugen, Kristagen and Ventfort at 0.2 g each per day. These are amounts of the named products. The paper gives no purified peptide content.

Protocol source ↗ · Original journal PDF, methods and Tables 1–3. Parent program report and Ministry of Defence project citation checked.

Results · Original journal PDF, methods and Tables 1–3. Parent program report and Ministry of Defence project citation checked.
MeasureResultComparison, timing and statistics
International Prostate Symptom Score20.94 ± 8.49 → 8.46 ± 2.78p<0.01
Urinary flow4.9 ± 2.3 → 9.1 ± 2.5 mL/sp<0.001
Urinary symptom quality-of-life item4.10 ± 1.01 → 2.53 ± 0.61p<0.001
Severe urinary symptoms61/150 → 14/150IPSS ≥20. The paper reports 40.7% → 9.3%.

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
150 veterans with benign prostatic hyperplasia. The same 150 are shown before and after treatment.
Source reviewed
Original journal PDF, methods and Tables 1–3. Parent program report and Ministry of Defence project citation checked.
Study limitations
  • There was no concurrent untreated comparator or single-product arm. The results cover the combination.
  • The tested Veziliut lot and its peptide content remain unclear. The two 150-person publications are part of the same parent program, and participant overlap remains unverified.

Reviewed 2026-11-14.

Read the source ↗

Lab research · 2016

Vladonix, Endoluten and other peptides in cultured human blood cells

In cultured blood cells, Crystagen raised lysate IL-18 to a printed median of 75.10 vs 39.06 pg/mL. The printed Crystagen interquartile range excludes its median.

Study notes and original source
2016In vitroFull text available

Vladonix, Endoluten and other peptides in cultured human blood cells

Six separately assayed peptide preparations supplied by the Khavinson laboratory. · Original journal article

M. V. Maksimenya, E. V. Fefelova, A. S. Bykova · Actual Problems of Humanities and Natural Sciences. 2016;12-3:97–100

Vladonix increased cell-lysate IL-18 to a median of 66.48 vs 39.06 pg/mL with saline and lowered IL-1RA to 3,765 vs 5,228 pg/mL. The study compared six preparations in cell culture.

Results and tables

Reported findings and study design

Saline-controlled cultures from 15 donors, 0.4 µg/mL for 24 hours. Lysate and supernatant were analyzed separately.

Population or model Peripheral-blood mononuclear cells from 15 volunteers. Mean donor age 41 ± 19 years, 73% men.

Dose, route and schedule

Cells were exposed to 0.4 µg/mL of each preparation or volume-matched saline for 24 hours at 37 °C. Cytokines were measured by ELISA in cell lysates and culture supernatant.

Protocol source ↗ · Original journal PDF, methods, Table 1 and culture-supernatant results

Results · Original journal PDF, methods, Table 1 and culture-supernatant results
MeasureResultComparison, timing and statistics
Vladonix · lysate IL-1866.48 vs 39.06 pg/mLMedian with Vladonix versus saline. · p < 0.001
Vladonix · lysate IL-1RA3,765 vs 5,228 pg/mLMedian with Vladonix versus saline. · p = 0.006
Endoluten · lysate IL-18 and IL-465.11 vs 39.06 and 28.40 vs 12.24 pg/mLEndoluten versus saline. · p = 0.02 and p < 0.001, respectively.
Crystagen and Cortexin · lysate IL-1875.10 and 60.02 vs 39.06 pg/mLEach preparation versus saline. Crystagen’s printed interval is inconsistent. · p = 0.004 and p = 0.04, respectively.
Vilon · lysate TNF-α and IL-1RA904.04 vs 598.05 and 4,056 vs 5,228 pg/mLVilon versus saline. · p = 0.045 and p = 0.02, respectively.
Epitalon · lysate IL-1RA4,346 vs 5,228 pg/mLEpitalon versus saline. · p = 0.047
Culture supernatantEndoluten IL-18 +33.46% and Vilon TNF-α +41.13%These were the only significant supernatant changes reported. Neither of the two Vladonix lysate findings was reported as significant in supernatant. · p = 0.02 and p = 0.035, respectively.
Table 1 · cell-lysate cytokines
Table 1 · cell-lysate cytokines
PreparationIL-18 (pg/mL)TNF-α (pg/mL)IL-4 (pg/mL)IL-1RA (pg/mL)
Saline39.06598.0512.245,228
Vladonix66.48*706.5417.623,765*
Endoluten65.11*429.0228.40*4,860
Crystagen75.10*505.2620.474,772
Vilon34.74904.04*9.964,056*
Epitalon30.62548.009.504,346*
Cortexin60.02*693.0015.044,921

Printed medians. Asterisks mark comparisons with saline at p < 0.05. The Crystagen IL-18 interquartile interval is printed as 66.46–70.62, which excludes the printed median.

The experiment measures cytokine concentrations after direct contact with cells. The clinical meaning and relevance to swallowing a capsule remain unknown.

Source for these results ↗ · Reviewed 2026-11-13

Population / setting
Peripheral-blood mononuclear cells from 15 volunteers. Mean donor age 41 ± 19 years, 73% men.
Source reviewed
Original journal PDF, methods, Table 1 and culture-supernatant results
Study limitations
  • The volunteers donated blood and did not receive treatment. Culture concentrations cannot establish oral exposure or clinical effects.
  • The Crystagen IL-18 median lies outside its printed interquartile interval. Some narrative percentages differ from ratios calculated from tabulated medians.

Reviewed 2026-11-13.

Read the source ↗

Comparison in people · 2018

Pinealon and Crystagen in a 28-rower study

The monograph reports changes in oxidative biomarkers, alongside little change in several blood counts. It does not establish individual effects of Pinealon and Crystagen.

Study notes and original source
2018Human comparative studyRussian-language source

Pinealon and Crystagen in a 28-rower study

· Molecular and Cellular Mechanisms of Peptidergic Regulation of Brain Functions, Chapter 6.1.2, pp. 168–182

Format: Molecular and Cellular Mechanisms of Peptidergic Regulation of Brain Functions, Chapter 6.1.2, pp. 168–182 · Reviewed: Reported methods, results and evidence limitations

V. Kh. Khavinson et al. · Molecular and Cellular Mechanisms of Peptidergic Regulation of Brain Functions, Chapter 6.1.2, pp. 168–182

The monograph reports changes in oxidative biomarkers, alongside little change in several blood counts. It does not establish individual effects of Pinealon and Crystagen.

Results and tables

Reported findings and study design

The monograph reports changes in oxidative biomarkers, alongside little change in several blood counts. It does not establish individual effects of Pinealon and Crystagen.

The authors describe stratified randomization and clinical, laboratory and oxidative-status measurements. Active supplement selection was individualized.

Population or model 28 rowers aged 18–30, 18 men and 10 women. Active and ordinary-training groups n=14 each.

Dose, route and schedule

One oral capsule twice a day during meals for ten days in the active group. Individual capsule payload and allocation by preparation are not recoverable for each endpoint.

Protocol source ↗ · Molecular and Cellular Mechanisms of Peptidergic Regulation of Brain Functions, Chapter 6.1.2, pp. 168–182

Results · Molecular and Cellular Mechanisms of Peptidergic Regulation of Brain Functions, Chapter 6.1.2, pp. 168–182
MeasureResultComparison, timing and statistics
Hemoglobin136.1 → 134.4 g/L active; 137.0 → 141.6 g/L controlSelected Table 6.6 means.
Leukocytes5.2 → 5.1 vs 5.9 → 5.8 ×10⁹/LActive versus ordinary-training group, Table 6.6.
Oxidative markersAuthors described lower lipid-peroxidation productsBiomarker results are separate from timed rowing.

The comparison group continued usual training. Heterogeneous formulations and small groups limit attribution. Participant overlap with Emirova’s older cytamin series remains uncertain.

Source for these results ↗ · Reviewed 2026-11-09

Population / setting
28 rowers aged 18–30, 18 men and 10 women. Active and ordinary-training groups n=14 each.
Source reviewed
Molecular and Cellular Mechanisms of Peptidergic Regulation of Brain Functions, Chapter 6.1.2, pp. 168–182
Study limitations
  • The comparison group continued usual training. Heterogeneous formulations and small groups limit attribution. Participant overlap with Emirova’s older cytamin series remains uncertain.

Reviewed 2026-11-09.

Read the source ↗

Comparison in people · 2012

Pinealon plus Crystagen in rhythmic gymnastics

Morning recovery heart rate decreased from 83.8 to 74.2 beats/min in the combined arm. Heart rate during full routines and individual elements showed no significant change.

Study notes and original source
2012Human comparative studyRussian-language source

Pinealon plus Crystagen in rhythmic gymnastics

· St. Petersburg Institute of Bioregulation and Gerontology, reproduced methodological report, Tables 2–3

Format: Reproduced original methodological report; comparison tables checked · Reviewed: Reported methods, results and evidence limitations

V. Kh. Khavinson, S. V. Trofimova, A. V. Trofimov, A. V. Dudkov, I. A. Viner, R. N. Terekhina, A. A. Lyshchev · St. Petersburg Institute of Bioregulation and Gerontology, reproduced methodological report, Tables 2–3

Morning recovery heart rate decreased from 83.8 to 74.2 beats/min in the combined arm. Heart rate during full routines and individual elements showed no significant change.

Results and tables

Reported findings and study design

Morning recovery heart rate decreased from 83.8 to 74.2 beats/min in the combined arm. Heart rate during full routines and individual elements showed no significant change.

Author-described stratified assignment. Heart rate during training tasks and recovery, with other laboratory and self-reported outcomes.

Population or model 20 elite female rhythmic gymnasts. Combination n=12; usual training n=8.

Dose, route and schedule

One capsule of each oral product twice daily with meals for 20 days. The comparison was usual training without matched placebo.

Protocol source ↗ · Reproduced original methodological report; comparison tables checked

Results · Reproduced original methodological report; comparison tables checked
MeasureResultComparison, timing and statistics
Morning recovery heart rate83.8±1.5 → 74.2±2.5 beats/minCombination arm, p<0.05 within group. Comparison arm 86.6±3.2 → 88.4±3.6.
Evening recovery heart rate87.4±2.3 → 77.6±1.7 beats/minCombination arm, p<0.05 within group. Comparison arm 84.3±3.1 → 83.7±2.4.
During routines and individual elementsNo statistically significant changes reportedTraining heart-rate measures are separate from performance judged in competition.

The report cannot isolate Pinealon or Crystagen and does not demonstrate competitive benefit.

Source for these results ↗ · Reviewed 2026-11-09

Population / setting
20 elite female rhythmic gymnasts. Combination n=12; usual training n=8.
Source reviewed
Reproduced original methodological report; comparison tables checked
Study limitations
  • Both preparations were given together. Publications from the same group may repeat this cohort.

Reviewed 2026-11-09.

Read the source ↗

Experiment described in a patent · 2011

Crystagen research trail: defined EDP peptide — US8057810B2

Selected T-cell markers changed during EDP-containing care, without established clinical immune-rejuvenation outcomes.

CD3-positive cells · 55.7 ± 2.6% after peptide-containing care versus 49.3 ± 2.2% conventional care; baseline 43.5 ± 2.3% · Immune-marker endpoint; significance annotation has an ambiguous comparator footnote

Study notes and original source
2011Patent / reported experimentsFull text available

Crystagen research trail: defined EDP peptide — US8057810B2

Patent-defined substance or composition · Patent publication

Format: Original patent text and indexed metadata · Reviewed: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.

Vladimir Khatskelevich Khavinson, Evgeny Iosifovich Grigoriev, Vladimir Victorivich Malinin, Galina Anatolievna Ryzhak · US8057810B2 · patent family 38314259

Selected T-cell markers changed during EDP-containing care, without established clinical immune-rejuvenation outcomes.

Results and tables

Reported patent results

Reported findings

Selected T-cell markers changed during EDP-containing care, without established clinical immune-rejuvenation outcomes.

EDP patent comparison in older adults aged 62–83: 38 receiving severity-adjusted adjunctive peptide and 32 conventional care.

Population or model EDP patent comparison in older adults aged 62–83: 38 receiving severity-adjusted adjunctive peptide and 32 conventional care.

Results · Clinical older-adult comparison and Table 4; immune-marker interpretation limited.
MeasureResultComparison, timing and statistics
CD3-positive cells55.7 ± 2.6% after peptide-containing care versus 49.3 ± 2.2% conventional care; baseline 43.5 ± 2.3%Immune-marker endpoint; significance annotation has an ambiguous comparator footnote
CD4/CD8 ratio1.4 after peptide versus 1.2 conventional care; baseline 1.1Surrogate marker, not a disease or survival endpoint
B-cell markerCD20 percentages 12.0 ± 0.7 versus 12.0 ± 0.4; baseline 12.3 ± 0.6No corresponding generalized improvement across all immune measures

Incompletely specified allocation, severity-dependent treatment and marker endpoints limit inference. These observations concern defined EDP; commercial Crystagen equivalence remains unverified.

Source for these results ↗ · Reviewed 2026-11-06

Population / setting
EDP patent comparison in older adults aged 62–83: 38 receiving severity-adjusted adjunctive peptide and 32 conventional care.
Source reviewed
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Study limitations
  • The sequence-level connection does not authenticate the composition or efficacy of a commercial Crystagen product.
  • Incompletely specified allocation, severity-dependent treatment and marker endpoints limit inference. These observations concern defined EDP; commercial Crystagen equivalence remains unverified.
  • Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
  • Status labels are Google Patents index snapshots for the displayed publication or application; each record lists the review date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.

Reviewed 2026-11-06.

Read the source ↗

Observational study · 2016

Personified prevention of diseases under the conditions of the Far North

A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.

Study notes and original source
2016Uncontrolled human reportFull text available

Personified prevention of diseases under the conditions of the Far North

Risk-assigned capsule program: Endoluten tissue extract and named synthetic peptide products; Cerluten also named in assignments · Journal publication

S. Trofimova, A. Trofimov, A. Koryakin, A. Chubukin, V. Ternovoy · Vrach. 2016;(6):64–66

A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.

Results and tables

Reported findings and study design

A personalized multi-preparation program recorded 18 → 10 sick-leave certificates and 119 → 60 days unfit for work between 2014 and 2015. The paper found no statistically reliable seasonal-morbidity improvement.

113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.

Population or model 113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.

Dose, route and schedule

One capsule of the assigned preparation daily for 20 days. Products were selected by risk assessment; all six products were not given to every participant.

Protocol source ↗ · Original PDF p.65

Results · Original publisher PDF pp.64–66; Table 2 visually checked
MeasureResultComparison, timing and statistics
Sick-leave certificates18 → 102014 → 2015; whole program
Days unfit for work119 → 602014 → 2015; whole program
Seasonal morbidityNo statistically reliable improvement reported
Narrative/table discrepancyNarrative 43.4% decrease; Table 2 gives 119 → 60 daysUnresolved source discrepancy; not interchangeable figures
Table 2 · Chronic-disease recurrence-related sick leave
Table 2 · Chronic-disease recurrence-related sick leave
Measure20142015
Sick-leave certificates1810
Days unfit for work11960

Historical comparison for the shared 113-worker program. Not preparation-specific results.

One shared cohort, not a separate trial for each named preparation. Genotype-guided assignments and other care prevent isolating a product effect. The narrative reports a 43.4% reduction, which does not reconcile with the table’s 119 → 60 days. The background 11,000-worker claim is not this cohort.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
113 Gazprom Dobycha Urengoy employees (74 men, 39 women), assessed in 2015; comparison with the preceding year, without a concurrent control.
Source reviewed
Original publisher PDF methods and clinical table checked; table visually verified.
Study limitations
  • One shared cohort, not a separate trial for each named preparation. Genotype-guided assignments and other care prevent isolating a product effect. The narrative reports a 43.4% reduction, which does not reconcile with the table’s 119 → 60 days. The background 11,000-worker claim is not this cohort.

Reviewed 2026-11-01.

Read the source ↗

Research record · 2014

Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process

Crystagen activated B-cell measures but did not cause renewal of the aging spleen. Vilon was associated with lower T-helper-cell apoptosis; Thymogen with lower apoptosis and increased B-cell proliferation.

Study notes and original source
2014Study design unresolvedEnglish abstract

Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

Short-peptide experimental preparations; marketed-product equivalence unresolved · Journal publication

Сhervyakova NA, Linkova NS, Chalisova NI, Koncevaya EA, Trofimova SV, Khavinson VK · Advances in gerontology = Uspekhi gerontologii 2014

Crystagen activated B-cell measures but did not cause renewal of the aging spleen. Vilon was associated with lower T-helper-cell apoptosis; Thymogen with lower apoptosis and increased B-cell proliferation.

Results and tables

Reported findings and study design

Crystagen activated B-cell measures but did not cause renewal of the aging spleen. Vilon was associated with lower T-helper-cell apoptosis; Thymogen with lower apoptosis and increased B-cell proliferation.

Experimental aging-spleen work; species and assay design not specified in the indexed abstract.

Population or model Experimental aging-spleen work; species and assay design not specified in the indexed abstract.

Results · Primary-publication indexed abstract
MeasureResultComparison, timing and statistics
Crystagen responseB-cell activation reported; no aging-spleen cell renewal
Other peptide responsesVilon: reduced T-helper apoptosis; Thymogen: B-cell proliferation with less apoptosis

The abstract does not establish the experimental model sufficiently to classify this as a human study or a specific animal/cell design. Commercial product equivalence is unverified.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
Experimental aging-spleen work; species and assay design not specified in the indexed abstract.
Source reviewed
Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Study limitations
  • The abstract does not establish the experimental model sufficiently to classify this as a human study or a specific animal/cell design. Commercial product equivalence is unverified.

Reviewed 2026-11-01.

Read the source ↗

Comparison in people · 2006

Crystagen after radiation exposure: Medical Center clinical report

In the low-dose radiation subgroup, CD4-positive cells were 32.1% after Crystagen plus usual care versus 29.7% after usual care alone. The table marks the change from baseline, with no reported between-group test.

Study notes and original source
2006Human comparative studyFull text available

Crystagen after radiation exposure: Medical Center clinical report

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Oral Crystagen as described in the report · Institute report / commercial reproduction

Originating institute; report reproduced in commercial collection · Reports on clinical studies of CYTOMAX and CYTOGEN products; PDF page 109

In the low-dose radiation subgroup, CD4-positive cells were 32.1% after Crystagen plus usual care versus 29.7% after usual care alone. The table marks the change from baseline, with no reported between-group test.

Results and tables

Reported findings and study design

40 received Crystagen plus conventional therapy and 30 received conventional therapy alone. The reported oral regimen was one to three capsules two to three times daily for 15–20 days. Table 2 covers the low-dose radiation subgroup (20 treated, 15 comparator).

Population or model 70 adults aged 38–69: 40 received adjunctive Crystagen and 30 received conventional therapy alone. Each arm included patients with low-dose radiation exposure and patients after radiation and chemotherapy.

Results · Medical Center report reproduced in the English compilation, PDF pages 109–110
MeasureResultComparison, timing and statistics
CD4-positive cells in the low-dose radiation subgroup32.1 ± 1.8% with Crystagen vs 29.7 ± 2.4% with conventional care. Shared baseline 26.3 ± 2.4%.The Crystagen value is marked p < 0.05 versus baseline.
CD3-positive cells in the low-dose radiation subgroup53.3 ± 2.2% with Crystagen vs 49.3 ± 2.3% with conventional care. Shared baseline 45.1 ± 2.1%.The Crystagen value is marked p < 0.05 versus baseline.
IgG in the low-dose radiation subgroup15.2 ± 1.5 g/L with Crystagen vs 15.4 ± 1.4 g/L with conventional care. Shared baseline 15.1 ± 1.2 g/L.The table gives no significance mark for IgG.

The report uses a shared baseline and gives no direct between-group statistical test for these outcomes.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
70 adults aged 38–69: 40 received adjunctive Crystagen and 30 received conventional therapy alone. Each arm included patients with low-dose radiation exposure and patients after radiation and chemotherapy.
Source reviewed
Report reproduction, PDF pages 109–112. Methods and Tables 1–2.
Study limitations
  • The report gives one shared baseline column and leaves allocation and masking unspecified.
  • The low-dose radiation table covers 20 treated patients and 15 conventional-care patients.
  • The clinical product is insufficiently characterized to establish equivalence with synthetic EDP.

Reviewed 2026-11-16.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗